All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-12-07T11:08:45.000Z

How do symptoms inform treatment decisions in MPN?

By Becky Gribbell, Jennifer Higgins, Lauren Lett, Jen Wyatt Green
Featured
Ruben A. Mesa
Dec 7, 2022
Share:
Learning objective: After reading this article, learners will be able to recall real-world data on the diagnosis, management, or monitoring of patients with MPN.

Bookmark this article

During the 14th International Congress of Myeloproliferative Neoplasms, the MPN Hub was pleased to speak to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked, How do symptoms inform treatment decisions in myeloproliferative neoplasms (MPN)?

How do symptoms inform treatment decisions in MPN?

Mesa opens by remarking on the range of different symptoms patients with MPN may experience and the effects these differing symptoms may have on disease presentation and progression. Mesa comments on symptoms as a marker of health-related quality of life and their subsequent use in informing the decision to initiate or alter treatment.

Mesa concludes by reiterating the importance of improving symptoms and quality of life as a cornerstone of treatment.

More about...
MPN Congress 2022Myeloproliferative neoplasms

Related articles

Add bookmark

What is the use for monoclonal antibodies in MPN?

During the 14th International Congress of Myeloproliferative Neoplasms, the MPN Hub was pleased to speak to Ann Mullally. We asked, What is the use for monoclonal antibodies in MPN?

Nov 14, 2022
Add bookmark

What is the use for monoclonal antibodies in MPN?

During the 14th International Congress of Myeloproliferative Neoplasms, the MPN Hub was pleased to speak to Ann Mullally. We asked, What is the use...

Nov 14, 2022
Add bookmark

Use of integrative medicine may correlate with improved symptoms and quality of life in patients with MPN

Myeloproliferative neoplasms (MPN) are associated with a high symptom burden and the risk of progression to acute myeloid leukemia (AML)....

Jan 7, 2021
Add bookmark

Use of integrative medicine may correlate with improved symptoms and quality of life in patients with MPN

Myeloproliferative neoplasms (MPN) are associated with a high symptom burden and the risk of...

Jan 7, 2021

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox